Please let us know if you agree to all of these cookies..
We are dedicated to developing next generation immunotherapies to transform the lives of patients with cancer.
F-star’s wholly owned pipeline generates first and best-in-class drug candidates that work with patients’ immune systems to stop tumors from evading the body’s defense mechanisms.
F-star’s proprietary tetravalent bispecific antibody format ensures focused, potent and safe activation of the patient’s immune system.
Our most advanced drug candidate, aiming to rescue checkpoint inhibitor failures, in a proof-of-concept Phase 2 trial in patients with head and neck cancer, who have developed acquired resistance to PD-1/PD-L1 immunotherapies.